ProNAi Therapeutics Inc (DNAI) was Downgraded by SunTrust to ” Neutral”. Earlier the firm had a rating of “Buy ” on the company shares. SunTrust advised their investors in a research report released on Jun 6, 2016.
Many Wall Street Analysts have commented on ProNAi Therapeutics Inc. ProNAi Therapeutics Inc was Downgraded by Jefferies to ” Hold” on Jun 6, 2016.
ProNAi Therapeutics Inc closed down -0.02 points or -0.31% at $6.38 with 5,79,647 shares getting traded on Friday. Post opening the session at $6.52, the shares hit an intraday low of $6.22 and an intraday high of $6.58 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Mar 24, 2016, Wendy Chapman (SVP Clinical Operations) sold 3,000 shares at $7.01 per share price. According to the SEC, on Jan 22, 2016, Wendi Rodigueza (Chief Scientific Officer) sold 3,000 shares at $9.86 per share price. On Jan 19, 2016, Nicholas Glover (CEO and President) sold 5,000 shares at $10.05 per share price, according to the Form-4 filing with the securities and exchange commission.
ProNAi Therapeutics Inc. is a clinical-stage oncology company. The Company develops and commercializes a portfolio of therapeutics based on its deoxyribonucleic acid interference (DNAi) technology platform for patients with cancer and hematological diseases. The Company’s lead DNAi product candidate PNT2258 treat cancers that overexpress BCL2 an oncogene known to be dysregulated in many types of cancer. Its platform consists of two components: Rationally-Designed DNAi Oligonucleotides and Lipid Nanoparticle (LNP) Delivery Technology. The Company has conducted two clinical trials for PNT2258: a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkins lymphoma (NHL). It has initiated Wolverine a Phase II trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.